Azitra reports FY2024 net loss of $9.0M; cash $4.6M; trial updates for ATR-12 and ATR-04

Azitra, Inc.

2024-FY EPS reported -$2.37 revenue$7,500

Net loss $9.0M vs $11.3M in FY2023; R&D expenses $4.7M, G&A $6.3M.
Cash $4.6M at Dec 31, 2024; additional $2.2M raised in Jan/Feb 2025.
Phase 1b trial of ATR-12 in Netherton syndrome ongoing; initial safety data expected H1 2025, topline by year-end.
FDA cleared IND and granted Fast Track for ATR-04 for EGFRi rash; multicenter Phase 1/2 to start H1 2025.
Closed $10M and $5M public offerings in 2024; IP portfolio strengthened.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.